Related Experiment Video
Updated: Aug 16, 2025
04:01
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
Published on: September 15, 2023
855
Post-radiotherapy cribriform-morular thyroid carcinoma
Arzu Or Koca1, Gülçin Güler Şimşek2
1Department of Endocrinology and Metabolism, Dr. Abdurrahman Yurtaslan Ankara Onkoloji Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
Journal of Clinical Laboratory Analysis
|December 19, 2022
Summary
Cribriform-morular thyroid carcinoma, a rare differentiated thyroid malignancy, is now recognized as a distinct entity. This case report highlights a 15-year-old patient who developed this rare thyroid cancer after neck radiotherapy.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- The 2022 World Health Organization classification reclassifies thyroid malignancy formerly known as cribriform-morular variant of papillary thyroid carcinoma.
- This rare thyroid cancer is now termed cribriform-morular thyroid carcinoma and is considered a tumor of unknown histogenesis.
Observation:
- A 15-year-old patient with a history of external neck radiotherapy for Hodgkin's disease is presented.
- The patient developed cribriform-morular thyroid carcinoma five years post-radiotherapy.
Findings:
- Diffuse nuclear beta-catenin expression was observed in the cribriform-morular thyroid carcinoma.
- This finding is associated with unresolved uncertainties regarding prognosis and follow-up.
Implications:
- The diagnosis and management of cribriform-morular thyroid carcinoma require careful consideration by cytopathologists and endocrinologists.
- Further research is needed to understand the prognostic implications of beta-catenin expression in this rare thyroid malignancy.
